3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Lymphoma, T-Cell, Peripheral
1
Inhibition of Autophagy Synergizes Anti-tumor Effect
1
Immunoblastic Lymphadenopathy
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Digestive System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor Cancer
1
Interventions
pembrolizumab
37
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
enfortumab vedotin
10
Carboplatin
10
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled